Trial Profile
A Single-center Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 01 Mar 2022 Results published in the Clinical Pharmacology in Drug Development
- 18 Dec 2017 Status changed from recruiting to completed.
- 17 Nov 2017 Planned End Date changed from 29 Nov 2017 to 22 Nov 2017.